Global PARP Inhibitors Market Assessment, By Drug Type [Olaparib, Niraparib, Rucaparib, Talazoparib, Veliparib, Others], By Application [Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer], By End-user [Specialty Clinics, Hospitals, Home Healthcare, Others], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies] By Region, Opportunities and Forecast, 2017-2031F

Global PARP inhibitors market is expected to experience significant growth over the forecast period owing to increase in investments towards research and development activities and rising prevalence of cancer.

Home>Industry Reports>Global PARP Inhibitors Market Assessment, Opportunities and Forecast, 2017-2031F

Global PARP inhibitors market is projected to witness a CAGR of 13.31% during the forecast period 2024-2031, growing from USD 6.44 billion in 2023 to USD 17.5 billion in 2031F. Increased investments in research and development activities and the increasing prevalence of cancer are providing lucrative growth opportunities to the market.

Poly (ADP-ribose) polymerase (PARPs) catalyze the transfer of ADP-ribose in proteins. PARP1 and PARP2 mediate the DNA repair process and play an essential role in maintaining genomic stability. PARP inhibitors prevent cancer cells from repairing, causing their death. These drugs mostly avoid affecting healthy cells and target cancer cells.

The PARP enzyme has a wide range of functions in a cell, such as DNA damage response, regulation of transcription, and apoptosis. PARP inhibitors exploit the concept of synthetic lethality. In this lethal phenomenon, cell can survive an isolated genetic event, whereas cell death occurs in the case of co-occurrence of multiple genetic events. They target cancer cells that have a defective homologous recombination DNA repair pathway.

The growing emphasis on enhancing the efficacy of PARP inhibitors owing to the increasing prevalence of cancer further supports the market expansion. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. The American Cancer Society estimated that in 2024, 12,740 women are expected to die due to ovarian cancer, and 19,680 new cases will be diagnosed in the United States.

Rising Cases of Breast Cancer Boost Market Demand

As per National Breast Cancer Foundation, one out of eight women will be diagnosed with breast cancer over the course of their lifetime. It was estimated that in 2023, 297,790 women and 2,800 men will get a diagnosis of invasive breast cancer. PARP inhibitors prevent the cancer cells from repairing damaged tumor DNA. Olaparib is used for the treatment of both early and metastatic breast cancer, and Talazoparib is used for the treatment of metastatic breast cancer.

Due to the growing prevalence of the disease, various organizations are providing additional funding to research institutions for better treatments and better prediction models for breast cancer. For instance, In November 2023, researchers from University of Washington, Seattle Children’s Cancer Consortium and Fred Hutchinson received additional funding from Breast Cancer Research Foundation (BCRF) to continue working on their ongoing studies. The Vice President for Clinical Affairs and a medical oncologist, Davidson received funding for another year to research the expanded applications of PARP inhibitors.

Increasing Research Activities Support the PARP Inhibitors Market Growth

PARP inhibitors have shown promising results since their clinical applications and were the first clinically approved drugs that were developed based on synthetic lethality. The inhibitors have been approved for use as maintenance treatment for cancer patients with BRCA mutations. The continuation of innovative explorations is expected to support the development of potent drugs with novel mechanisms.

In 2023, the American Society of Clinical Oncology (ASCO) presented new updates on the utilization of PARP inhibitors for the treatment of ovarian cancer. Significant attempts are being made to combine PARP inhibitors with immune checkpoint inhibitors (ICIs) in patients suffering from advanced ovarian cancer. It was demonstrated in the DUO-O trial that the addition of maintenance Olaparib and anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor durvalumab to the standard of care prolongs progression free survival in cases on advanced ovarian cancer. PARP inhibitors present a promising avenue in the therapy for ovarian cancer. Ongoing research and development activities for novel agent combinations hold promise for future advancements.

North America Expected to Account for a Significant Market Share

The strong presence of various key players in the region, availability of skilled workforce, increasing government initiatives to strengthen the healthcare sector, and rising investments towards research and development activities by both research institutions and market players is supporting the expansion of the North America PARP inhibitors market. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. Due to the surge in cases of cancer in the region, the requirement for advanced cancer therapeutics, including PARP inhibitors is increasing. The different regulatory bodies in the country are focusing on studying the effects of novel cancer treatments and granting them approvals.

In 2023, Pfizer, Inc., one of the leading pharmaceutical and biotechnology corporations in the United States, announced positive results from their phase 3 TALAPRO-2 study of TALZENNA (Talazoparib), an oral PARP inhibitor, combined with enzalutamide. They demonstrated a clinically meaningful and statistically significant improvement in radiographic progression free survival, with or without HRR gene mutations. The United States Food and Drug Administration (FDA) granted priority review of TALZENNA combined with enzalutamide for treatment of men with metastatic castration-resistant prostate cancer.

Preference for Olaparib Anticipated to Increase

Increasing adoption of Olaparib PARP inhibitors for treatment of pancreatic cancer, ovarian cancer, and both metastatic and early breast cancer is facilitating the market growth. In 2022, an article published in Cancer Discovery discussed the 5-year analysis of data, showing that the patients that received Olaparib for 2 years had a median progression free survival of 3.5 years longer than those who received placebo.

In January 2024, the post-hoc analysis of phase 3 PROpel trial (NCT03732820) presented at the 2024 Genitourinary Cancers Symposium confirmed that the treatment with frontline Olaparib and abiraterone acetate benefits patients with HRR mutated metastatic castration-resistant prostate cancer. The post-hoc exploratory analysis that examined the aggregate subgroups of non-BRCA-mutated, BRCA-mutate, non-HRR-mutated, and HRR-mutated disease further demonstrated favorable radiographic progression free survival outcomes with abiraterone plus Olaparib as opposed to abiraterone alone.

Retail Pharmacies Expected to Witness Significant Growth

The provision of branded as well as generic drugs, with other pharmaceutical products under one roof is bolstering the popularity of retail pharmacies in various regions across the globe. The pharmacists in these pharmacies are trusted counsel by many and often explain the side effects of different drugs to their customers. These pharmacies are an integral component of the healthcare ecosystem in various countries across the globe, accounting for a significant PARP inhibitors market share.

Meanwhile, online pharmacies are expected to rapidly expand in the coming years. The growth can be attributed to providing various benefits by online pharmacies, including privacy, discounts, fast shipping, delivery, convenience, and others. The online purchase of medicines from verified and legitimate internet pharmacies has become an accepted practice among various developed countries.

Future Market Scenario (2024 – 2031F)

·         Various clinical trials are underway to investigate the next generation of PARP inhibitors. PARP enzymes play different roles at different cell cycle stages, therefore, it is essential to understand the interaction network in the cells for the exploration of novel potential therapies.

·         Additional studies are required for determining if alternating drug combinations, including PARP inhibitors, anti-angiogenic agents, and immunotherapy are able to offer clinical benefits to patients suffering from ovarian cancer.

·         Recently, in RUBY Part 2 Phase 3 trial it was noted that the combination of Zejula (niraparib) and Jemperli (dostarlimab) significantly improved progression-free survival in recurrent or primary advanced endometrial cancer. The results have reinforced the development approach of using Jemperli in immuno-oncology-based combination therapies.

Report Scope

PARP Inhibitors Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global PARP inhibitors market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute

Details

Base Year of the Analysis

2023

Historical Period

2017-2022

Forecast Period

2024-2031F

Projected Growth Rate

CAGR of 13.31% between 2024-2031F

Revenue Forecast in 2031

USD 17.5 billion

Units

Revenue in USD billion

Segments Covered

Drug Type, Application, End-user, Distribution Channel

Regions Covered

North America, Europe, South America, Asia-Pacific, Middle East and Africa

Key Companies Profiled

Pfizer, Inc., GlaxoSmithKline Plc., Genentech, Inc., AbbVie Inc., Sierra Oncology, Inc., Ono Pharmaceutical Co. Ltd., Johnson & Johnson Services, Inc., Jiangsu Hengrui Medicine Co., Ltd., Repare Therapeutic, Inc., Karyopharm Therapeutics Inc.

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfil your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, PARP inhibitors market has been segmented into the following categories:

·         By Drug Type

o   Olaparib

o   Niraparib

o   Rucaparib

o   Talazoparib

o   Veliparib

o   Others

·         By Application

o   Ovarian Cancer

o   Breast Cancer

o   Pancreatic Cancer

o   Prostate Cancer

·         By End-user

o   Specialty Clinics

o   Hospitals 

o   Home Healthcare

o   Others

·         By Distribution Channel

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

·         By Region

o   North America

o   South America

o   Europe

o   Asia-Pacific

o   Middle East & Africa

Key Players Landscape and Outlook

Key participants in global PARP inhibitors market include Pfizer, Inc., GlaxoSmithKline Plc., Genentech, Inc., AbbVie Inc., and Sierra Oncology, Inc. The rising investments towards research and development activities and increasing prevalence of different types of cancer is providing lucrative growth opportunities to the market.

In 2023, FDA approved Pfizer drug, Talazoparib (Talzenna) with enzalutamide for HRR gene mutated metastatic castration-resistant prostate cancer. The efficacy of the drug was evaluated in a multi-cohort, randomized, placebo-controlled, and double-blind trial that enrolled 399 patients with homologous recombination repair gene mutated metastatic castration-resistant prostate cancer.

Key Players Operating in the Global PARP Inhibitors Market are:

·         Pfizer, Inc.

·         GlaxoSmithKline Plc.

·         Genentech, Inc.

·         AbbVie Inc.

·         Sierra Oncology, Inc.

·         Ono Pharmaceutical Co. Ltd.

·         Johnson & Johnson Services, Inc.

·         Jiangsu Hengrui Medicine Co., Ltd.

·         Repare Therapeutic, Inc.

·         Karyopharm Therapeutics Inc.

Markets and Data report answers the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments, and what are the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global PARP inhibitors market, you may approach our team at info@marketsandata.com

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Executive Summary

4.       Global PARP Inhibitors Market Outlook, 2017-2031F

4.1.    Market Size & Forecast

4.1.1.By Value

4.1.2.By Volume

4.2.    By Drug Type

4.2.1.Olaparib

4.2.2.Niraparib

4.2.3.Rucaparib

4.2.4.Talazoparib

4.2.5.Veliparib

4.2.6.Others

4.3.    By Application

4.3.1.Ovarian Cancer

4.3.2.Breast Cancer

4.3.3.Pancreatic Cancer

4.3.4.Prostate Cancer

4.4.    By End-user

4.4.1.Specialty Clinics

4.4.2.Hospitals  

4.4.3.Home Healthcare

4.4.4.Others

4.5.    By Distribution Channel

4.5.1.Hospital Pharmacies

4.5.2.Retail Pharmacies

4.5.3.Online Pharmacies

4.6.    By Region

4.6.1.North America

4.6.2.South America

4.6.3.Europe

4.6.4.Asia-Pacific

4.6.5.Middle East & Africa

4.7.    By Company Market Share (%), 2023

5.       Global PARP Inhibitors Market Outlook, By Region, 2017-2031F

5.1.   North America*

5.1.1.Market Size & Forecast

5.1.1.1.              By Value

5.1.1.2.              By Volume

5.1.2.By Drug Type

5.1.2.1.              Olaparib

5.1.2.2.              Niraparib

5.1.2.3.              Rucaparib

5.1.2.4.              Talazoparib

5.1.2.5.              Veliparib

5.1.2.6.              Others

5.1.3.By Application

5.1.3.1.              Ovarian Cancer

5.1.3.2.              Breast Cancer

5.1.3.3.              Pancreatic Cancer

5.1.3.4.              Prostate Cancer

5.1.4.By End-user

5.1.4.1.              Specialty Clinics

5.1.4.2.              Hospitals

5.1.4.3.              Home Healthcare

5.1.4.4.              Others

5.1.5.By Distribution Channel

5.1.5.1.              Hospital Pharmacies

5.1.5.2.              Retail Pharmacies

5.1.5.3.              Online Pharmacies

5.1.6.United States*

5.1.6.1.              Market Size & Forecast

5.1.6.1.1.                    By Value

5.1.6.1.2.                    By Volume

5.1.6.2.              By Drug Type

5.1.6.2.1.                    Olaparib

5.1.6.2.2.                    Niraparib

5.1.6.2.3.                    Rucaparib

5.1.6.2.4.                    Talazoparib

5.1.6.2.5.                    Veliparib

5.1.6.2.6.                    Others

5.1.6.3.              By Application

5.1.6.3.1.                    Ovarian Cancer

5.1.6.3.2.                    Breast Cancer

5.1.6.3.3.                    Pancreatic Cancer

5.1.6.3.4.                    Prostate Cancer

5.1.6.4.              By End-user

5.1.6.4.1.                    Specialty Clinics

5.1.6.4.2.                    Hospitals

5.1.6.4.3.                    Home Healthcare

5.1.6.4.4.                    Others

5.1.6.5.              By Distribution Channel

5.1.6.5.1.                    Hospital Pharmacies

5.1.6.5.2.                    Retail Pharmacies

5.1.6.5.3.                    Online Pharmacies

5.1.7.Canada

5.1.8.Mexico

*All segments will be provided for all regions and countries covered

5.2.   Europe

5.2.1.Germany

5.2.2.France

5.2.3.Italy

5.2.4.United Kingdom

5.2.5.Russia

5.2.6.Netherlands

5.2.7.Spain

5.2.8.Turkey

5.2.9.Poland

5.3.   Asia-Pacific

5.3.1.India

5.3.2.China

5.3.3.Japan

5.3.4.Australia

5.3.5.Vietnam

5.3.6.South Korea

5.3.7.Indonesia

5.3.8.Philippines

5.4.   South America

5.4.1.Brazil

5.4.2.Argentina

5.5.   Middle East & Africa

5.5.1.Saudi Arabia

5.5.2.UAE

5.5.3.South Africa

6.       Market Mapping, 2023

6.1.    By Drug Type

6.2.    By Application

6.3.    By End-user

6.4.    By Distribution Channel

6.5.    By Region

7.       Macro Environment and Industry Structure

7.1. Supply Demand Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1.       Political Factors

7.4.2.       Economic System

7.4.3.       Social Implications

7.4.4.       Technological Advancements

7.4.5.       Environmental Impacts

7.4.6.       Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter’s Five Forces Analysis

7.5.1.       Supplier Power

7.5.2.       Buyer Power

7.5.3.       Substitution Threat

7.5.4.       Threat from New Entrant

7.5.5.       Competitive Rivalry

8.       Market Dynamics

8.1. Growth Drivers

8.2. Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1. Patent Landscape

9.2. Regulatory Approvals

9.3. Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.                     Competition Matrix of Top Five Market Leaders

10.2.                     Market Revenue Analysis of Top Five Market Leaders (in %, 2023)

10.3.                     Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.                     SWOT Analysis (For Five Market Players)

10.5.                     Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.                     Pfizer, Inc.

13.1.1.    Company Details

13.1.2.    Key Management Personnel

13.1.3.    Products & Services

13.1.4.    Financials (As reported)

13.1.5.    Key Market Focus & Geographical Presence

13.1.6.    Recent Developments

13.2.                     GlaxoSmithKline Plc.

13.3.                     Genentech, Inc.

13.4.                     AbbVie Inc.

13.5.                     Sierra Oncology, Inc.

13.6.                     Ono Pharmaceutical Co. Ltd.

13.7.                     Johnson & Johnson Services, Inc.

13.8.                     Jiangsu Hengrui Medicine Co., Ltd.

13.9.                     Repare Therapeutic, Inc.

13.10.                  Karyopharm Therapeutics Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.   Strategic Recommendations

15.   About Us & Disclaimer

List of Figures

Figure 1. Global PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 2. Global PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 3. Global PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 4. Global PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 5. Global PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 6. Global PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 7. Global PARP Inhibitors Market Share (%), By Region, 2017-2031F

Figure 8. North America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 9. North America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 10. North America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 11. North America PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 12. North America PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 13. North America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 14. North America PARP Inhibitors Market Share (%), By Country, 2017-2031F

Figure 15. United States PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 16. United States PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 17. United States PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 18. United States PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 19. United States PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 20. United States PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 21. Canada PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 22. Canada PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 23. Canada PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 24. Canada PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 25. Canada PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 26. Canada PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 27. Mexico PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 28. Mexico PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 29. Mexico PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 30. Mexico PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 31. Mexico PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 32. Mexico PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 33. Europe PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 34. Europe PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 35. Europe PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 36. Europe PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 37. Europe PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 38. Europe PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 39. Europe PARP Inhibitors Market Share (%), By Country, 2017-2031F

Figure 40. Germany PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 41. Germany PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 42. Germany PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 43. Germany PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 44. Germany PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 45. Germany PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 46. France PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 47. France PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 48. France PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 49. France PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 50. France PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 51. France PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 52. Italy PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 53. Italy PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 54. Italy PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 55. Italy PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 56. Italy PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 57. Italy PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 58. United Kingdom PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 59. United Kingdom PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 60. United Kingdom PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 61. United Kingdom PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 62. United Kingdom PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 63. United Kingdom PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 64. Russia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 65. Russia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 66. Russia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 67. Russia PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 68. Russia PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 69. Russia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 70. Netherlands PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 71. Netherlands PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 72. Netherlands PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 73. Netherlands PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 74. Netherlands PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 75. Netherlands PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 76. Spain PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 77. Spain PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 78. Spain PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 79. Spain PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 80. Spain PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 81. Spain PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 82. Turkey PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 83. Turkey PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 84. Turkey PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 85. Turkey PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 86. Turkey PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 87. Turkey PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 88. Poland PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 89. Poland PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 90. Poland PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 91. Poland PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 92. Poland PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 93. Poland PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 94. South America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 95. South America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 96. South America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 97. South America PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 98. South America PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 99. South America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 100. South America PARP Inhibitors Market Share (%), By Country, 2017-2031F

Figure 101. Brazil PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 102. Brazil PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 103. Brazil PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 104. Brazil PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 105. Brazil PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 106. Brazil PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 107. Argentina PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 108. Argentina PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 109. Argentina PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 110. Argentina PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 111. Argentina PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 112. Argentina PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 113. Asia-Pacific PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 114. Asia-Pacific PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 115. Asia-Pacific PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 116. Asia-Pacific PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 117. Asia-Pacific PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 118. Asia-Pacific PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 119. Asia-Pacific PARP Inhibitors Market Share (%), By Country, 2017-2031F

Figure 120. India PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 121. India PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 122. India PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 123. India PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 124. India PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 125. India PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 126. China PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 127. China PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 128. China PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 129. China PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 130. China PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 131. China PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 132. Japan PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 133. Japan PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 134. Japan PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 135. Japan PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 136. Japan PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 137. Japan PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 138. Australia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 139. Australia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 140. Australia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 141. Australia PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 142. Australia PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 143. Australia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 144. Vietnam PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 145. Vietnam PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 146. Vietnam PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 147. Vietnam PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 148. Vietnam PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 149. Vietnam PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 150. South Korea PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 151. South Korea PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 152. South Korea PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 153. South Korea PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 154. South Korea PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 155. South Korea PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 156. Indonesia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 157. Indonesia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 158. Indonesia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 159. Indonesia PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 160. Indonesia PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 161. Indonesia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 162. Philippines PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 163. Philippines PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 164. Philippines PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 165. Philippines PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 166. Philippines PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 167. Philippines PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 168. Middle East & Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 169. Middle East & Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 170. Middle East & Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 171. Middle East & Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 172. Middle East & Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 173. Middle East & Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 174. Middle East & Africa PARP Inhibitors Market Share (%), By Country, 2017-2031F

Figure 175. Saudi Arabia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 176. Saudi Arabia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 177. Saudi Arabia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 178. Saudi Arabia PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 179. Saudi Arabia PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 180. Saudi Arabia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 181. UAE PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 182. UAE PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 183. UAE PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 184. UAE PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 185. UAE PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 186. UAE PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 187. South Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F

Figure 188. South Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F

Figure 189. South Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F

Figure 190. South Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F

Figure 191. South Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F

Figure 192. South Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F

Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 195. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What are the regions covered in the final report of global PARP inhibitors market?

arrowup
Heart

Global E-bike Battery Market Assessment, Opportunities and Forecast, 2017-2031F

The increased popularity of e-bikes along with the increasing adoption of compact vehicles for adventure sport and exploration is propelling the market expansion. ....Read More

Published on

April 2024

4,500

Heart

Global Chloroxylenol Market Assessment, Opportunities and Forecast, 2017-2031F

Global chloroxylenol market is expected to experience significant growth over the forecast period owing to the antimicrobial properties of chloroxylenol, increasing emphasis on maintaining skin health and personal hygiene, and growing threat of surgi....Read More

Published on

April 2024

4,500

Heart

Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F

Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.....Read More

Published on

April 2024

4,500

Heart

Global Magnesium Citrate Market Assessment, Opportunities and Forecast, 2017-2031F

Global magnesium citrate market will witness significant growth over the forecast period owing to rapid expansion of the pharmaceutical sector and increasing research and development activities.....Read More

Published on

April 2024

4,500

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979